TheEdgeResearch
Home / Stocks / BOVNF

BioInvent International AB (publ) (BOVNF)

OTC Healthcare Biotechnology
$0.22 ▲ +0.00%
Market Cap
$14.7M
Sector
Healthcare
Industry
Biotechnology
Beta
0.02
52-Wk Range
0.224-3.29
CEO
Martin Welschof
Country
SE
Currency
USD

BioInvent International AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $0.22, up 0.00% on the session, giving a market capitalisation of $14.7M. On trailing twelve-month figures it carries a trailing P/E of -0.28, a net margin of -1217.7%. Its beta of 0.02 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.28
Price / Sales
3.44
Price / Book
0.68
EV / EBITDA
0.14
Gross margin
100.0%
Operating margin
-1242.0%
Net margin
-1217.7%
Return on equity
—
Debt / equity
0.10
Current ratio
2.80
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
109
IPO date
2013-09-03
Headquarters
Lund, SN, SE
About BioInvent International AB (publ)

BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.

Comparable companies

BioInvent International AB (publ) is most often compared with the following Healthcare names:

ATRXBPMUFCASIFCLVLFCSPHFCUVLMLLCFSLN
More research on BOVNF
BOVNF technical analysis BOVNF TheEdge Score Compare against peers
Open full interactive analysis & DCF →